Stock market update: Nifty Pharma index advances 0.35% in an upbeat market

Stock market update: Nifty Pharma index advances 0.35% in an upbeat market
ETMarkets.com
Rate Story
Share
Font Size
Save
Comment
Synopsis

The Nifty Pharma index was trading 0.35 per cent up at 12692.05.

markets-shutterShutterstock.com
India 10-year bond yield jumped 0.38 per cent to 6.03 after trading in 6.01 - 6.04 range.
NEW DELHI: The Nifty Pharma index traded positive around 10:24AM(IST)on Wednesday in an upbeat market.

Lupin(up 1.47 per cent), Glenmark Pharmaceuticals(up 1.24 per cent), Gland Pharma(up 1.1 per cent), Torrent Pharmaceuticals(up 0.8 per cent) and Zydus Lifesciences(up 0.79 per cent) were among the top gainers.

Granules India(down 0.75 per cent), Ipca Laboratories(down 0.33 per cent), Sanofi India(down 0.27 per cent), Cipla(down 0.13 per cent) and Glaxosmithkline Pharmaceuticals(down 0.03 per cent) were the top losers on the index.

The Nifty Pharma index was up 0.35 per cent at 12692.05 at the time of writing this report.

Benchmark NSE Nifty50 index was up 60.95 points at 18114.25, while the BSE Sensex was up 223.08 points at 60878.8.

Among the 50 stocks in the Nifty index, 30 were trading in the green, while 20 were in the red.

Shares of Zomato Ltd., YES Bank, , PNB and were among the most traded shares on the NSE.

Shares of JTL Infra, , Ltd., Homesfy Realty Ltd. and hit their fresh 52-week highs in today's trade, while FSN E-Comm(Nykaa), Anlon Technology ., Chaman Metallics Ltd., Inds. and Omkar Speciality hit fresh 52-week lows in trade.
Experience Your Economic Times Newspaper, The Digital Way!

Read More News on

(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

...more
Pick the best stocks for yourself
Powered by
Read before you invest. Insights on GlaxoSmithKline Pharmaceuticals Ltd.. Explore Now